DXP Enterprises (NASDAQ:DXPE – Get Free Report) and Cyclacel Pharmaceuticals (NASDAQ:BGMS – Get Free Report) are both industrials companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.
Profitability
This table compares DXP Enterprises and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DXP Enterprises | 4.45% | 18.67% | 5.66% |
| Cyclacel Pharmaceuticals | -74.40% | -24.24% | -21.39% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for DXP Enterprises and Cyclacel Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DXP Enterprises | 0 | 2 | 3 | 0 | 2.60 |
| Cyclacel Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
DXP Enterprises presently has a consensus target price of $183.00, suggesting a potential upside of 19.72%. Given DXP Enterprises’ stronger consensus rating and higher probable upside, analysts clearly believe DXP Enterprises is more favorable than Cyclacel Pharmaceuticals.
Risk and Volatility
DXP Enterprises has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500.
Institutional & Insider Ownership
74.8% of DXP Enterprises shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 22.0% of DXP Enterprises shares are held by company insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares DXP Enterprises and Cyclacel Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DXP Enterprises | $2.02 billion | 1.18 | $88.68 million | $6.01 | 25.43 |
| Cyclacel Pharmaceuticals | $1.86 million | 2.05 | -$3.00 million | ($2.40) | -0.24 |
DXP Enterprises has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than DXP Enterprises, indicating that it is currently the more affordable of the two stocks.
Summary
DXP Enterprises beats Cyclacel Pharmaceuticals on 12 of the 14 factors compared between the two stocks.
About DXP Enterprises
DXP Enterprises, Inc. is a distributor of industrial products and provider of related services. It supplies maintenance, repair and operating products, including bearings, power-transmission components, safety equipment and other industrial supplies to customers in a range of industries. The company also provides pump and rotating-equipment services, such as pump repair and packaged pumping systems, as well as supply-chain services that support customers’ procurement and inventory-management needs.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research has centered on compounds that target cell-cycle regulation and other processes involved in cancer-cell growth. The company’s investigational drug candidates have included fadraciclib, a cyclin-dependent kinase inhibitor, and sapacitabine, an oral nucleoside analogue. These candidates have been studied for potential use in hematologic cancers and solid tumors; they are not approved medicines.
Receive News & Ratings for DXP Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DXP Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.
